PCT | Jotup

Curative Biotechnology, Inc. Files Patent on Ophthalmic Formulation

Retrieved on:

Wednesday, May 24, 2023

Retina, Patent Cooperation Treaty, PCT, Application, OTC, Metformin, RPE, Rare, Choroid

Boca Raton, FL, May 24, 2023 (GLOBE NEWSWIRE) -- Curative Biotechnology Inc. (OTC: CUBT) (“Curative Biotech” or the “Company”), a development-stage biomedical company focused on novel therapies for rare diseases and conditions, announced today that a Patent Cooperation Treaty (PCT) application was duly filed in the U.S. Receiving Office on May 22, 2023, claiming priority to U.S. Provisional Application No. 63/345,759, filed May 25, 2022.

Key Points:

Topical Administration Capable of Delivering Metformin to Choroid, RPE, and Retina
Boca Raton, FL, May 24, 2023 (GLOBE NEWSWIRE) -- Curative Biotechnology Inc. (OTC: CUBT) (“Curative Biotech” or the “Company”), a development-stage biomedical company focused on novel therapies for rare diseases and conditions, announced today that a Patent Cooperation Treaty (PCT) application was duly filed in the U.S.
Receiving Office on May 22, 2023, claiming priority to U.S.
63/345,759, filed May 25, 2022.
The Application has been accorded International Application No.

NurExone Reports First Quarter 2023 Financial Results and Provides Corporate Update

Retrieved on:

Wednesday, May 24, 2023

As the Company scales, NurExone intends to continue expanding its patent portfolio in order to strengthen its competitive moat.

Key Points:

As the Company scales, NurExone intends to continue expanding its patent portfolio in order to strengthen its competitive moat.
Research and development expenses were US$0.37 million in the first quarter of 2023, compared to US$0.28 million in the same quarter in 2022.
Financial (income) expenses were (US$0.01) million in the first quarter of 2023, compared to US$0.09 million in the same period in 2022.
Net loss was US$0.70 million in the first quarter of 2023, compared to a net loss of US$2.31 million in the first quarter of 2022.

Terran Biosciences announces new breakthroughs in the chemistry of MDMA and its enantiomers and analogs, discovers new salts and polymorphs, publishes PCT application.

Retrieved on:

Friday, May 26, 2023

MDAI, Therapy, MEAI, PTSD, PCT, MDE, Literature, Patent, Post-traumatic stress disorder, Patient, USE, MBDB, Empathy, Terran, SALTS, MDMA, MDEA, Pharmaceutical industry

MDMA is the most studied empathogen to date and has been shown to be an effective treatment for post-traumatic stress disorder (PTSD) in multiple phase 3 trials.

Key Points:

MDMA is the most studied empathogen to date and has been shown to be an effective treatment for post-traumatic stress disorder (PTSD) in multiple phase 3 trials.
Historically, MDMA has only been developed as a single salt and the crystal structures of its enantiomers had not been characterized.
As previously reported, Terran found that the S enantiomer of MDEA had significant advantages over the (R)-MDEA in preclinical models.
Terran is also developing the S enantiomer of MBDB which was shown to have significant advantages over (R)-MBDB in preclinical models.

Chairman Chen Yanshun attended the opening ceremony of SID Display Week 2023 and addressed at BOE Innovation Ecosystem Forum

Retrieved on:

Friday, May 26, 2023

Patent, Communication, Speech, Internet of things, Heart, Multimedia, LCD, TFT-LCD, SID, PCT, Future, PDP, OLED, BOE, Generation 6 (NASCAR), System, Development, Innovation, MLED, CRT, DIA, Airline, Television

Mr. Chen Yanshun, Chairman of BOE, and Mr. Gao Wenbao, President of BOE were invited to attend the opening ceremony of SID Display Week.

Key Points:

Mr. Chen Yanshun, Chairman of BOE, and Mr. Gao Wenbao, President of BOE were invited to attend the opening ceremony of SID Display Week.
At the same time, BOE hosted the "Define the Future – BOE Innovation Ecosystem Forum" during the event, paying homage to the 30th anniversary of its founding with world-leading technologies of display.
Chen Yanshun, Chairman of BOE, attended the forum and delivered a speech.
As a prestigious organization dedicated to the global display industry, the SID is celebrating its 61st birthday this year.

Hundreds of Global Scientists Gather in 2023 Greater Bay Area Science Forum Held in Nansha, Guangzhou

Retrieved on:

Monday, May 22, 2023

GUANGZHOU, China, May 22, 2023 /PRNewswire/ -- The 2023 Greater Bay Area Science Forum (GSF) kicked off on May 21 in Nansha, Guangzhou, Guangdong Province.

Key Points:

GUANGZHOU, China, May 22, 2023 /PRNewswire/ -- The 2023 Greater Bay Area Science Forum (GSF) kicked off on May 21 in Nansha, Guangzhou, Guangdong Province.
The application volume of enterprises' PCT accounts for 94.43% of the volume of PCT application of the GBA.
Official data shows that in the field of artificial intelligence and life and health, more than 1,000 companies have gathered in Nansha.
After the Hong Kong University of Science and Technology (Guangzhou) started in Nansha, the Science and Technology Park of Hong Kong University of Science and Technology and the Nangsha Incubation Base of Hong Kong Science and Technology Parks have accelerated.

Hundreds of Global Scientists Gather in 2023 Greater Bay Area Science Forum Held in Nansha, Guangzhou

Retrieved on:

Monday, May 22, 2023

GUANGZHOU, China, May 22, 2023 /PRNewswire/ -- The 2023 Greater Bay Area Science Forum (GSF) kicked off on May 21 in Nansha, Guangzhou, Guangdong Province.

Key Points:

GUANGZHOU, China, May 22, 2023 /PRNewswire/ -- The 2023 Greater Bay Area Science Forum (GSF) kicked off on May 21 in Nansha, Guangzhou, Guangdong Province.
The application volume of enterprises' PCT accounts for 94.43% of the volume of PCT application of the GBA.
Official data shows that in the field of artificial intelligence and life and health, more than 1,000 companies have gathered in Nansha.
After the Hong Kong University of Science and Technology (Guangzhou) started in Nansha, the Science and Technology Park of Hong Kong University of Science and Technology and the Nangsha Incubation Base of Hong Kong Science and Technology Parks have accelerated.

Terran Biosciences discovers what may be the first new salts, co-crystals, and polymorphs of psilocybin in history, publishes PCT patent application, and files psilocybin Drug Master File (DMF) with FDA

Retrieved on:

Friday, May 19, 2023

Psilocybin, GMP, Human, Drug Master File, Depression, Therapy, SOLID, History, PCT, Literature, Hydrogen chloride, Patent, Patient, DMF, Ecosystem, Salt, FDA, Terran, SALTS, Pharmaceutical industry

Psilocybin is one of the main active compounds in psychedelic mushrooms and has been used by humans for thousands of years.

Key Points:

Psilocybin is one of the main active compounds in psychedelic mushrooms and has been used by humans for thousands of years.
Recent clinical studies suggest psilocybin is efficacious in treating depression.
According to the literature, there are three main polymorphic forms of zwitterionic psilocybin: form A, form B, and form A' (A-Prime).
Terran also replicated this comprehensive set of studies with the psilocin prodrug O-acetylpsilocin, resulting in additional novel salts and polymorphs of that compound as well.

Enveric Biosciences Receives Notice of Allowance from USPTO for Novel Prodrug of Psilocin

Retrieved on:

Thursday, May 18, 2023

Enveric Biosciences, Inc. (NASDAQ: ENVB) (“Enveric” or the “Company”), a biotechnology company dedicated to the development of novel small-molecule therapeutics for the treatment of anxiety, depression, and addiction disorders, today announced that it has received a Notice of Allowance from the United States Patent and Trademark Office (USPTO) for a patent application involving EB-373, the Company’s new chemical entity (NCE) psilocin prodrug being developed for the treatment of anxiety disorder.

Key Points:

Enveric Biosciences, Inc. (NASDAQ: ENVB) (“Enveric” or the “Company”), a biotechnology company dedicated to the development of novel small-molecule therapeutics for the treatment of anxiety, depression, and addiction disorders, today announced that it has received a Notice of Allowance from the United States Patent and Trademark Office (USPTO) for a patent application involving EB-373, the Company’s new chemical entity (NCE) psilocin prodrug being developed for the treatment of anxiety disorder.
The soon-to-issue patent, titled, “C4-Carbonothioate-Substituted Tryptamine Derivatives and Methods of Using,” contains composition of matter claims for a family of novel prodrug derivatives of psilocin, including EB-373, Enveric’s lead product candidate.
The USPTO issues a Notice of Allowance after making the determination that a patent should be granted from an application.
Additionally, Enveric has filed further composition of matter patent applications with the USPTO for psilocin prodrugs, including compositions comprising a crystalline molecular structure.

Pan Cancer T appoints Rachel Abbott to succeed Katrien Reynders-Frederix as Chief Executive Officer

Retrieved on:

Friday, May 12, 2023

TNBC, CSO, Supervisory board, Erasmus MC, PCT, TCR, Entrepreneurship, Pan-cancer analysis, Patient, Supervision, Management, Medical imaging

ROTTERDAM, May 12, 2023 - Pan Cancer T B.V. , a biotech spin-off from Erasmus MC dedicated to the discovery and development of next-generation TCR-T therapies against solid tumors, today announces the appointment of Dr. Rachel Abbott as Chief Executive Officer (CEO).

Key Points:

ROTTERDAM, May 12, 2023 - Pan Cancer T B.V. , a biotech spin-off from Erasmus MC dedicated to the discovery and development of next-generation TCR-T therapies against solid tumors, today announces the appointment of Dr. Rachel Abbott as Chief Executive Officer (CEO).
Rachel steps up from her current role as Pan Cancer T’s Chief Scientific Officer (CSO), succeeding Katrien Reynders-Frederix who has served as CEO since the company’s inception.
“I am very honoured to accept the Supervisory Board’s and shareholders’ offer to lead Pan Cancer T and I look forward to building on the strong foundation laid by Katrien,” said Rachel Abbott.
We look forward as a Supervisory Board to working with Rachel and supporting her in the transformation of PCT as a leading player in the field.”

Terran Biosciences announces publication of four PCT patent applications covering breakthroughs in novel empathogens, including improved versions of methylone, ethylone, MDEA, MDAI, and MBDB

Retrieved on:

Thursday, May 11, 2023

The discoveries include novel deuterated forms, enantiomerically pure forms, as well as novel salts, polymorphs, and co-crystals of racemic methylone, R-methylone and S-methylone.

Key Points:

The discoveries include novel deuterated forms, enantiomerically pure forms, as well as novel salts, polymorphs, and co-crystals of racemic methylone, R-methylone and S-methylone.
Terran believes that therapeutic options for patients should be equally diverse, with unique psychedelics and empathogens tailored to specific patient needs.
Terran completed what is believed to be the first comprehensive salt and polymorph screen performed to date on this compound.
Terran completed additional improvements including the synthesis of deuterated forms of racemic methylone, R-methylone, and S-methylone with improved pharmacokinetics.